Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 501–600 of 1,004
Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice
Bregni, G., Telli, T. A., Camera, S., Deleporte, A., Moretti, L., Bali, A. M., Liberale, G., Holbrechts, S., Hendlisz, A., & Sclafani, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101948 · Cited by 93
Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Glimelius, B. L. G., & Oliveira, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp128 · Cited by 92
Alternative clinical end points in rectal cancer—are we getting closer?
Glynne-Jones, R., Mawdsley, S., Pearce, T., & Buyse, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl173 · Cited by 88
Kim, S. H., Park, I. J., Joh, Y.-G., & Hahn, K.-Y. (2006) · Surgical Endoscopy · doi:10.1007/s00464-005-0599-2 · Cited by 88
Nishigori, H., Ito, M., Nishizawa, Y., Nishizawa, Y., Kobayashi, A., Sugito, M., & Saito, N. (2013) · World Journal of Surgery · doi:10.1007/s00268-013-2428-4 · Cited by 88
Canda, A. E., Terzi, C., Görken, İ. B., Öztop, İ., Sökmen, S., & Füzün, M. (2009) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0807-y · Cited by 88
“Randomized trials have demonstrated improved oncological outcomes and lower toxicity of preoperative CRT [1, 12].”
BackgroundVelenik, V., Ocvirk, J., Mušič, M. M., Bračko, M., Anderluh, F., Oblak, I., Edhemović, I., Brecelj, E., Kropivnik, M., & Omejc, M. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-105 · Cited by 90
Goldberg, R. M., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1728 · Cited by 103
Daniels, I. R., Fisher, S. E., Heald, R. J., & Moran, B. J. (2007) · Colorectal Disease · doi:10.1111/j.1463-1318.2006.01116.x · Cited by 99
Perez, R. O., Habr‐Gama, A., Julião, G. P. S., Lynn, P. B., Sabbagh, C., Proscurshim, I., Campos, F. G., Gama-Rodrigues, J. J., Nahas, S. C., & Buchpiguel, C. A. (2014) · Techniques in Coloproctology · doi:10.1007/s10151-013-1113-9 · Cited by 87
“preferred treatment alternatives for patients with locally advanced distal rectal cancer due to improved local disease control [1].”
Yeo, S., Kim, D. Y., Kim, T. H., Jung, K. H., Hong, Y. S., Chang, H. J., Park, J. W., Lim, S.-B., Choi, H. S., & Jeong, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1682 · Cited by 87
Kang, J., Kim, Y. C., Kim, H., Kim, Y. W., Hur, H., Kim, J. S., Min, B. S., Kim, H., Lim, J. S., Seong, J., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.066 · Cited by 87
Marks, J. H., Mizrahi, B., Dalane, S., Nweze, I. C., & Marks, G. (2010) · Surgical Endoscopy · doi:10.1007/s00464-010-1028-8 · Cited by 91
Mellon, E. A., Jin, W. H., Frakes, J. M., Centeno, B. A., Strom, T. J., Springett, G. M., Malafa, M. P., Shridhar, R., Hodul, P. J., & Hoffe, S. E. (2017) · Acta Oncologica · doi:10.1080/0284186x.2016.1256497 · Cited by 86
Hawkins, A. T., Albutt, K. H., Wise, P. E., Alavi, K., Sudan, R., Kaiser, A. M., & Bordeianou, L. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3750-9 · Cited by 103
“these cancers, rendering a sphincter-preserving approach feasible in many cases.(7) These anatomic and pathologic discoveries paralleled the development of technological advances, such as circular staplers, that further facilitated low pelvic anastomoses.”
BackgroundGambacorta, M. A., Masciocchi, C., Chiloiro, G., Meldolesi, E., Macchia, G., van Soest, J., Peters, F. P., Collette, L., Gérard, J., Ngan, S. Y., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.09.026 · Cited by 94
Self-citationFuture direction of total neoadjuvant therapy for locally advanced rectal cancer
Kagawa, Y., Smith, J. J., Fokas, E., Watanabe, J., Cercek, A., Greten, F. R., Bando, H., Shi, Q., García‐Aguilar, J., Romesser, P. B., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00900-9 · Cited by 96
“A pooled analysis of seven randomized trials 23,48,60–64 of neoadjuvant LCCRT for LARC found that the best time interval between LCCRT and surgery to achieve pCR in LARC was 10 weeks 65 .”
Self-citationChen, M., Wu, X., Yu, R., Li, C., Wang, L., Shen, W., & Lu, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045388 · Cited by 88
Myerson, R. J., Tan, B. R., Hunt, S. R., Olsen, J. R., Birnbaum, E. H., Fleshman, J. W., Gao, F., Hall, L. E., Kodner, I. J., Lockhart, A. C., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.12.028 · Cited by 91
Katz, M. S., Minsky, B. D., Saltz, L. B., Riedel, E., Chessin, D. B., & Guillem, J. G. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.033 · Cited by 88
Siegel, R., Burock, S., Wernecke, K., Kretzschmar, A., Dietel, M., Loy, V., Koswig, S., Budach, V., & Schlag, P. M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-50 · Cited by 98
“The recently published results from the CAO/ARO/ AIO-94 trial report that preoperative combined radiochemotherapy (RCT) is superior to postoperative RCT in terms of outcome [ 6 ].”
ResultPark, J. W., Lim, S., Kim, D. Y., Jung, K. H., Hong, Y. S., Chang, H. J., Choi, H. S., & Jeong, S. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.08.057 · Cited by 101
Kristiansen, C., Loft, A., Berthelsen, A. K., Graff, J., Lindebjerg, J., Bisgaard, C., & Jakobsen, A. K. M. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-9095-1 · Cited by 86
“Despite this radical surgical approach, the rate of locoregional recurrence still leaves room for improvement.(1) It is well documented that preoperative radiotherapy reduces the risk of local recurrence of rectal cancer.”
BackgroundRosenberg, R., Herrmann, K., Gertler, R., Künzli, B. M., Essler, M., Lordick, F., Becker, K., Schuster, T., Geinitz, H., Maak, M., et al. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-008-0616-8 · Cited by 89
“Preoperative radio(chemo)therapy in locally advanced rectal carcinoma is an established standard procedure since the publication of randomized multi-center trials [1–3].”
Smith, K. D., Tan, D., Das, P., Chang, G. J., Kattepogu, K., Feig, B. W., Skibber, J. M., & Rodríguez-Bigas, M. A. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181bdfc27 · Cited by 88
“On the basis of the recently completed prospective, randomized trial, comparing preoperative to postoperative chemoradiotherapy (CRT) for patients with locally advanced rectal cancer, preoperative CRT has emerged as the standard of care.(1) The addition of 5-fluorouracil (5-FU) and preoperative radiation significantly…”
BackgroundNissan, A., Stojadinovic, A., Shia, J., Hoos, A., Guillem, J. G., Klimstra, D. S., Cohen, A. M., Minsky, B. D., Paty, P. B., & Wong, W. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2968 · Cited by 87
Martoni, A. A., Fabio, F. D., Pinto, C., Castellucci, P., Pini, S., Ceccarelli, C., Cuicchi, D., Iacopino, B., Tullio, P. D., Giaquinta, S., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq433 · Cited by 92
Liersch, T., Langer, C., Ghadimi, Β. M., Kulle, B., Aust, D. E., Baretton, G. B., Schwabe, W., Häusler, P., Heinz Becker, A., & Jakob, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2739 · Cited by 85
Self-citationA Gene Expression Signature for Chemoradiosensitivity of Colorectal Cancer Cells
Spitzner, M., Emons, G., Krämer, F., Gaedcke, J., Rave‐Fränk, M., Scharf, J., Burfeind, P., Becker, H., Beißbarth, T., Ghadimi, Β. M., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.023 · Cited by 97
“however, some tumors will have a complete pathologic response and others will be completely resistant (8, 9).”
Bertolini, F., Chiara, S., Bengala, C., Antognoni, P., Dealis, C., Zironi, S., Malavasi, N., Scolaro, T., Depenni, R., Jovic, G., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.04.065 · Cited by 84
Helbling, D., Bodoky, G., Gautschi, O. P., Sun, H., Bosman, F. T., Gloor, B., Burkhard, R., Winterhalder, R., Madlung, A., Rauch, D., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds519 · Cited by 89
“Neoadjuvant chemoradiotherapy (CRT) is frequently used to downstage LARC tumors and to enable surgery to be more effective and provide locoregional control [1–3].”
Zhao, R., Wang, H., Zhou, Z., Zhou, Q., & Mulholland, M. W. (2014) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000022 · Cited by 86
Bujko, K., Michalski, W., Kępka, L., Nowacki, M. P., Nasierowska-Guttmejer, A. M., Tokar, P., Dymecki, D., Pawlak, M., Lesniak, T., Richter, P., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.08.065 · Cited by 84
Perez, R. O., Habr‐Gama, A., Julião, G. P. S., Gama-Rodrigues, J. J., Sousa, A. H. S. E., Campos, F. G., Imperiale, A. R., Lynn, P. B., Proscurshim, I., Nahas, S. C., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.01.096 · Cited by 85
Marks, J. H., Valsdóttir, E. B., Rather, A., Nweze, I. C., Newman, D. A., & Chernick, M. R. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181dadeb4 · Cited by 88
Ortholan, C., François, É., Thomas, O., Benchimol, D., Baulieux, J., Bosset, J.-F., & Gérard, J. P. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0263-x · Cited by 84
Hunter, C. J., Garant, A., Vuong, T., Artho, G. P., Lisbona, R., Tekkis, P. P., Abulafi, M., & Brown, G. M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2036-1 · Cited by 84
Li, J., Liu, H., Yin, J., Liu, S., Hu, J., Du, F., Yuan, J., Lv, B., Fan, J., Leng, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6093 · Cited by 84
Arredondo, J., Baixauli, J., Pastor, C., Chopitea, A., Sola, J. J., González, I., Cienfuegos, J. A., Martínez, P., Rodríguez, J., & Hernández-Lizoáin, J. L. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1539-4 · Cited by 84
“In recent years, a growing amount of data has consistently suggested the potential benefits of preoperative chemotherapy [7, 8] as is the case in other locally advanced gastrointestinal tumors [9].”
BackgroundSchaap, D. P., Boogerd, L. S. F., Konishi, T., Cunningham, C., Ogura, A., García‐Aguilar, J., Beets, G. L., Suzuki, T., Toda, S., Lee, I. K., et al. (2020) · British journal of surgery · doi:10.1093/bjs/znaa009 · Cited by 83
Laforest, A., Bretagnol, F., Mouazan, A. S., Maggiori, L., Ferron, M., & Panis, Y. H. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2012.02956.x · Cited by 90
Doll, D., Gertler, R., Maak, M., Friederichs, J., Becker, K., Geinitz, H., Kriner, M., Nekarda, H., Siewert, J. R., & Rosenberg, R. (2008) · World Journal of Surgery · doi:10.1007/s00268-008-9838-8 · Cited by 84
Negri, F., Campanini, N., Camisa, R., Pucci, F., Bui, S., Ceccon, G., Martinelli, R., Fumagalli, M., Losardo, P., Crafa, P., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604131 · Cited by 83
“Multidisciplinary treatment of rectal cancer has evolved over the years from adjuvant chemoradiation to preoperative radiation and, more recently, to preoperative combined chemoradiation, in view of an improved toxicity and local control (Sauer et al, 2004).”
Prognostic Value of Quality of Life and Pain in Patients with Locally Recurrent Rectal Cancer
You, Y. N., Halim, H., Chang, G. J., Rodrı́guez-Bigas, M. A., & Skibber, J. M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1218-6 · Cited by 83
“Recent advances in multimodality therapy and wide acceptance of total mesorectal excision (TME) have significantly improved the care of patients with rectal cancer.(1,2) Rates of local pelvic failure after primary curative therapy have declined from 20–30%, to only 6–11% in the setting of clinical trials and specializ…”
The Importance of the Pathologist’s Role in Assessment of the Quality of the Mesorectum
Bosch, S. L., & Nagtegaal, I. D. (2012) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0124-7 · Cited by 92
“A number of clinical trials over the last 20 years have demonstrated the benefits of neoadjuvant therapy in rectal carcinoma [4, 6, 34, 35].”
Calvo, F. Á., Serrano, J., Díaz-González, J. A., Gómez-Espí, M., Lozano, E. B., García, R. P., de la Mata, D., Arranz, J. Á., Alfonso, P. G., Pérez-Manga, G., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl085 · Cited by 92
“Preoperative chemoradiation with fluoropirimidines has been reported to promote sphincter preservation compared with postoperative chemoradiation in a small subset analysis [13], but this feature remains controversial in recent prospective trials evaluation with similar methodology [14]; on the other hand, pelvic dise…”
BackgroundMelton, G. B., Lavely, W. C., Jacene, H. A., Schulick, R. D., Choti, M. A., Wahl, R. L., & Gearhart, S. L. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0170-7 · Cited by 84
“In particular, advanced locoregional primary rectal cancer management frequently involves neoadjuvant chemotherapy and/or radiation therapy followed by definitive surgical tumor resection.(2) Despite these advances, up to 38% of patients with rectal cancer will eventually die having recurrent disease.”
BackgroundDas, P., Lin, E. H., Bhatia, S., Skibber, J. M., Rodrı́guez-Bigas, M. A., Feig, B. W., Chang, G. J., Hoff, P. M., Eng, C., Wolff, R. A., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.07.1374 · Cited by 82
Baik, S. H., Kim, N. K., Lee, Y. C., Kim, H., Lee, K. Y., Sohn, S. K., & Cho, C. H. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9171-0 · Cited by 82
“Sauer et al.20 reported that neoadjuvant CRT improved local control compared to adjuvant CRT. Neoadjuvant CRT has a potential advantage of curative surgery and sphincter preservation in patients with low-lying tumors.”
BackgroundNijkamp, J. A., de Jong, R., Sonke, J., Remeijer, P., van Vliet, C., & Marijnen, C. A. M. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.022 · Cited by 88
“The LR rates can be further reduced by adding pre-operative (chemo-) radiation [5–8].”
Glynne‐Jones, R., Dunst, J., & Sebag‐Montefiore, D. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj052 · Cited by 85
“The recent results of the German CAO/ARO/AIO-94 study [9] are likely to increase the use of preoperative therapy in most of Europe, compared with a general preference for postoperative therapy in the USA.”
BackgroundResultWang, Y., Cummings, B., Catton, P. A., Dawson, L. A., Kim, J., Ringash, J. G., Wong, R. K. S., Yi, Q., & Brierley, J. D. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.09.001 · Cited by 82
“about 3 months from the start of radiation) [12].”
BackgroundMultiparametric MRI of Rectal Cancer in the Assessment of Response to Therapy: A Systematic Review
Hötker, A. M., García‐Aguilar, J., & Gollub, M. J. (2014) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000127 · Cited by 87
Bökkerink, G. M. J., de Graaf, E. J. R., Punt, C. J. A., Nagtegaal, I. D., Rütten, H., Nuyttens, J. J. M. E., van Meerten, E., Doornebosch, P. G., Tanis, P. J., Derksen, E., et al. (2011) · BMC Surgery · doi:10.1186/1471-2482-11-34 · Cited by 86
“The percentage of patients with involved lymph nodes is much lower after neoadjuvant CRT [24,25], probably because CRT has sterilised tumour containing lymph nodes.”
BackgroundComplete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study
Perez, K. J., Safran, H., Sikov, W. M., Vrees, M. D., Klipfel, A. A., Shah, N. J., Schechter, S., Oldenburg, N. B. E., Pricolo, V. E., Rosati, K., et al. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000149 · Cited by 83
“Vomiting 2 (5) 0 (0) Anorexia/fatigue 4 (10) 0 (0) Diarrhea 9 (5) 1 (2) Dehydration 1 (2) 0 (0) ALT/AST 0 (0) 0 (0) Electrolyte 2 (5) 0 (0)”
Emile, S. H., Horesh, N., Freund, M. R., Garoufalia, Z., Gefen, R., Silva‐Alvarenga, E., Maron, D. J., DaSilva, G., & Wexner, S. D. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6116 · Cited by 83
Tumor Scatter After Neoadjuvant Therapy for Rectal Cancer: Are We Dealing with an Invisible Margin?
Hayden, D. M., Jakate, S. M., Mora-Pinzon, M. C., Giusto, D., Francescatti, A. B., Brand, M. I., & Saclarides, T. J. (2012) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318269fdb3 · Cited by 81
Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity
Hoff, P. M., Saad, E. D., Costa, F. P., Coutinho, A. K., Caponero, R., Prolla, G., & Gansl, R. C. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.10.004 · Cited by 87
Knauer, S. K., Bier, C., Schlag, P., Fritzmann, J., Dietmaier, W., Rödel, F., Klein‐Hitpaß, L., Kovács, A. F., Döring, C., Hansmann, M., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.12.4305 · Cited by 81
Neoadjuvant therapy for gastric cancer: current evidence and future directions.
Newton, A. D., Datta, J., Loaiza‐Bonilla, A., Karakousis, G. C., & Roses, R. E. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.047 · Cited by 87
Kim, H. J., Choi, G., Park, J. S., Park, S. Y., Lee, H. J., Woo, I. T., & Park, I. K. (2017) · Surgical Endoscopy · doi:10.1007/s00464-017-5948-4 · Cited by 82
Torres-Roca, J. F. (2012) · Personalized Medicine · doi:10.2217/pme.12.55 · Cited by 81
Lutz, M. P., Zalcberg, J. R., Glynne‐Jones, R., Ruers, T. J. M., Ducreux, M. P., Arnold, D., Aust, D. E., Brown, G., Bujko, K., Cunningham, C., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.010 · Cited by 92
Intraoperative radiation therapy for colon and rectal cancers: a clinical review
Haddock, M. G. (2017) · Radiation Oncology · doi:10.1186/s13014-016-0752-1 · Cited by 80
“Preoperative chemoradiation is preferred in the adjuvant treatment of rectal cancer based on improved local control and reduced toxicity [27].”
BackgroundWest, M. A., Astin, R., Moyses, H. E., Cave, J., White, D., Levett, D. Z. H., Bates, A. S., Brown, G. M., Grocott, M. P. W., & Jack, S. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1566775 · Cited by 87
Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer
Zaborowski, A. M., Stakelum, Á., & Winter, D. C. (2019) · British journal of surgery · doi:10.1002/bjs.11171 · Cited by 85
Hagemans, J. A. W., van Rees, J. M., Alberda, W. J., Rothbarth, J., Nuyttens, J. J. M. E., van Meerten, E., Verhoef, C. K., & Burger, J. W. A. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.10.037 · Cited by 86
Bordeianou, L., Maguire, L. H., Alavi, K., Sudan, R., Wise, P. E., & Kaiser, A. M. (2014) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-014-2528-y · Cited by 80
“One trial did demonstrate a 20 % increase in the rate of anterior resection, but this finding was seen only in subgroup analysis and important differences in tumor characteristics were observed between nonradiated and radiated groups.(55) Meta-analyses of randomized trials, however, do not support increased rates of L…”
ResultOptimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Sun, Z., Adam, M. A., Kim, J., Shenoi, M. M., Migaly, J., & Mantyh, C. R. (2016) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.12.017 · Cited by 81
Kulkarni, T., Gollins, S., Maw, A., Hobson, P., Byrne, R., & Widdowson, D. J. (2008) · Colorectal Disease · doi:10.1111/j.1463-1318.2007.01451.x · Cited by 85
Kim, J. C., Takahashi, K., Yu, C. S., Kim, H. C., Kim, T. W. B., Ryu, M. H., Jong Heon, K. I. M., & Mori, T. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318070d587 · Cited by 81
“We observed postoperative complications, including urinary difficulty, in 25% of our patients after TME, similar to the reported rates of 23% to 36%.(5,10) Anastomosis leakage, a troublesome morbidity after LAR regardless of adjuvant radiation or TME, occurred in 3% to 21% of patients.”
BackgroundResultInfluentialYang, J., Chen, Q., Jindou, L., & Cheng, Y. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25921 · Cited by 92
“The possible reason is that neoadjuvant chemoradiation can reduce the tumor stage, increase the local control, and significantly reduce the residual tumor cells after operation, which reduces the pelvic implantation after anastomotic leakage.(91,92) F IGURE 5 A, Meta‐analysis of rectal cancer disease‐free survival aft…”
BackgroundSaklani, A. P., Lim, D. R., Hur, H., Min, B. S., Baik, S. H., Lee, K. Y., & Kim, N. K. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1756-z · Cited by 79
Complete Clinical Response after Neoadjuvant Chemoradiation for Distal Rectal Cancer
Habr‐Gama, A., Perez, R. O., Proscurshim, I., & Gama-Rodrigues, J. J. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.08.001 · Cited by 82
Prognostic Groups in 1,676 Patients with T3 Rectal Cancer Treated without Preoperative Radiotherapy
Eriksen, M., Wibe, A., Haffner, J. F. W., & Wiig, J. N. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0757-1 · Cited by 80
“Accumulating evidence suggests that preoperative chemoradiotherapy is associated with better effect and reduced toxicity compared with postoperative.(11,29) The crucial point is whether local tumor extent and node status can be predicted preoperatively and by which modality.”
BackgroundLocally Recurrent Rectal Cancer: Prognostic Factors and Long-Term Outcomes of Multimodal Therapy
Pacelli, F., Tortorelli, A. P., Rosa, F., Bossola, M., Sánchez, A. M., Papa, V., Valentini, V., & Doglietto, G. B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0737-5 · Cited by 79
Pugh, S. A., Shinkins, B., Fuller, A., Mellor, J., Mant, D., & Primrose, J. M. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001351 · Cited by 87
Pelvic Radiation and Normal Tissue Toxicity
Nicholas, S., Chen, L., Choflet, A., Fader, A. N., Guss, Z. D., Hazell, S. Z., Song, D. Y., Tran, P. T., & Viswanathan, A. N. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.04.010 · Cited by 85
Sanoff, H. K., Moon, D. H., Moore, D. T., Boles, J., Bui, C., Blackstock, W., O'Neil, B. H., Subramaniam, S., McRee, A. J., Carlson, C., et al. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.02.021 · Cited by 72
Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma
Abraha, I., Aristei, C., Palumbo, I., Lupattelli, M., Trastulli, S., Cirocchi, R., Florio, R. D., & Valentini, V. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002102.pub3 · Cited by 101
“The preoperative approach has been compared with postoperative radiotherapy in randomised trials and has been shown to result in a lower risk of local recurrence and less toxicity compared with a postoperative approach (Sauer 2004; Sebag-Montefiore 2009).”
BackgroundResultKim, T. G., Park, W., Choi, D. H., Park, H. C., Kim, S., Cho, Y. B., Yun, S. H., Kim, H. C., Lee, W. Y., Lee, J., et al. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1797-3 · Cited by 78
“(RT) against locoregional recurrence, TME with neoadjuvant CRTor RT is now the standard treatment for locally advanced rectal cancer [3–5].”
MethodHa, H. I., Kim, A. Y., Yu, C. S., Park, S. H., & Ha, H. K. (2013) · European Radiology · doi:10.1007/s00330-013-2936-5 · Cited by 78
“During the last decade, the standard therapy for advanced rectal cancer has shifted from postoperative chemoradiation therapy to preoperative chemoradiation therapy (CRT) [1].”
BackgroundZhou, Z., Liu, S., Zhang, T., Chen, L., Xia, J., Hu, Z.-D., & Li, B. (2014) · Surgical Oncology · doi:10.1016/j.suronc.2014.10.003 · Cited by 83
“This regimen's superiority, in terms of local control, was demonstrated in the German rectal cancer trial, when compared with postoperative chemoradiotherapy [1,7].”
BackgroundHasegawa, J., Nishimura, J., Mizushima, T., Miyake, Y., Kim, H. M., Takemoto, H., Tamagawa, H., Noura, S., Fujii, M., Fujie, Y., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2417-9 · Cited by 80
Liersch, T., Meller, J., Bittrich, M., Kulle, B., Becker, H., & Goldenberg, D. M. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9328-x · Cited by 79
Self-citationGilbert, A., Ziegler, L. E., Martland, M., Davidson, S. E., Efficace, F., Sebag‐Montefiore, D., & Velikova, G. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.02.021 · Cited by 85
Tran, C.-L., Udani, S., Holt, A. D., Arnell, T. D., Kumar, R. R., & Stamos, M. J. (2006) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.08.061 · Cited by 79
Koeberle, D., Burkhard, R., von Moos, R., Winterhalder, R., Hess, V., Heitzmann, F., Ruhstaller, T., Terraciano, L. M., Neuweiler, J., Bieri, G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604297 · Cited by 83
“Many attempts have been made to increase the convenience and activity of preoperative 5-fluorouracil (5-FU)-based CRT. Evidence from phase II trials suggests that the oral fluoropyrimidine capecitabine (Xelodas; F Hoffmann-La Roche Ltd, Basel, Switzerland) has similar activity to that of protracted 5-FU infusional CRT…”
InfluentialQu, X., Zhou, D. F., Lu, J., Qin, D., Zhou, J. M., & Liu, H.-J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.010 · Cited by 89
“documented all instances of toxicity in their cohort of patients [63].”
BackgroundShao, Y., Liu, Z., Song, X., Sun, R., Zhou, Y., Zhang, D., Sun, H., Huang, J., Wu, C., Gu, W., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1318 · Cited by 78
Frequency of HER-2 Positivity in Rectal Cancer and Prognosis
Conradi, L., Styczen, H., Sprenger, T., Wolff, H. A., Rödel, C. M., Nietert, M. M., Homayounfar, K., Gaedcke, J., Kitz, J., Talaulicar, R., et al. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318272ff4d · Cited by 78
“Follow-up time Mean 36 59 40 Range 13-113 11-156 17-93 Cancer-related death 5 (11) 25 (17) 10 (14) HER-2 expression in cUICC II/III rectal cancer cells HER-2 resection specimens (n=225) IHC 0 1 (3) 19 (15) 10 (17) IHC 1+ 3 (8) 18 (14) 9 (16) IHC 2+ S-ISH neg 18 (45) 64 (50) 23 (40) S-ISH pos 8 (20) 14 (11) 7 (12) IHC…”
Self-citationVliegen, R. F. A., Dresen, R. C., Beets, G. L., Gooszen, A. W., Kessels, A. G. H., van Engelshoven, J. M. A., & Beets‐Tan, R. G. H. (2008) · Abdominal Imaging · doi:10.1007/s00261-007-9341-y · Cited by 77
“Additionally, large randomized trials have shown that neo-adjuvant therapy improves local tumor control even further, regardless of optimized surgical techniques [3, 4 ]. The advances in rectal cancer treatment have provoked differentiated neo-adjuvant treatment strategies based on anatomical preoperative identifiable…”
Unresectable Colorectal Cancer Can Be Cured With Multimodality Therapy
Mathis, K. L., Nelson, H., Pembérton, J. H., Haddock, M. G., & Gunderson, L. L. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318187ed4a · Cited by 78
Contin, P., Kulu, Y., Bruckner, T. M., Sturm, M., Welsch, T., Müller-Stich, B. P., Huber, J. C., Büchler, M. W., & Ulrich, A. B. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1780-z · Cited by 82
“These findings are in line with previous reports [49, 57–59].”
ResultLi, J., Ji, J., Cai, Y., Li, X., Li, Y., Wu, H., Xu, B., Dou, F., Li, Z., Bu, Z., et al. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.07.030 · Cited by 78
“, where the rate of anastomotic leakage of any grade is 11% [33].”
BackgroundResultJakob, C., Liersch, T., Meyer, W., Becker, H., Baretton, G. B., & Aust, D. E. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1060 · Cited by 78
Self-citationOverview of Systemic Therapy for Colorectal Cancer
Goodwin, R. A., & Asmis, T. R. (2009) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0029-1242465 · Cited by 86
Davey, K., Heriot, A. G., Mackay, J., Drummond, E. G. P., Hogg, A., Ngan, S. Y., Milner, A., & Hicks, R. J. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9244-1 · Cited by 78
Kim, D., Kim, D. Y., Kim, T. H., Jung, K. H., Chang, H. J., KyungSohn, D., Lim, S., Choi, H. S., Jeong, S., & Park, J. (2006) · Cancer · doi:10.1002/cncr.21794 · Cited by 77
“overall survival.(5) As preoperative CRT has become more popular, several prognostic factors have been proposed, and lymph node status has been shown to be a very important prognostic factor associated with disease-free survival.”
BackgroundNonoperative Management of Rectal Cancer
Habr‐Gama, A., Julião, G. P. S., & Perez, R. O. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.09.004 · Cited by 85
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.